Corrigendum

OPEN ACCESS

EMBO Molecular Medicine

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review

Marilena V Iorio & Carlo M Croce

Correction to: *EMBO Mol Med* (2012) 4: 143–159. DOI 10.1002/emmm.201100209 | Published online 20 February 2012

This article, published in the March 2012 issue of *EMBO Molecular Medicine*, contained text passages similar to those from a number of previous publications, many by the same authors: "Cancer microRNAs: from subtype profiling to predictors of response to therapy" by Chan E, Pardo DE, Weidhaas JB in *Trends Mol Med* 17: 235–243; "Targeting microRNAs in cancer: rationale, strategies and challenges" by Garson R, Marcucci G, Croce CM in *Nat Rev Drug Discov* 9: 775–789; "MicroRNAs in cancer: small molecules with a huge impact" by Iorio MV, Croce CM in *J Clin Oncol* 27: 5848–5856; and "Breast cancer and microRNAs: therapeutic impact" by Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E in *Breast* 20 Suppl. 3: S63–S70. Formal citations to the original articles were inadvertently omitted.

Similarly, a number of later publications overlap with text from this reference without formal citations. These are as follows: "microRNA: new players in metastatic process" by Triulzi T, Iorio MV, Tagliabue E, Casalini P in *Oncogene and cancer—from bench to clinic*, Siregar Y (ed.), Chapter 16. Rijeka: InTech; "microRNA involvement in human cancer" by Iorio MV, Croce CM in *Carcinogenesis* 33: 1126–1133; and "Causes and consequences of microRNA dysregulation" by Iorio MV, Croce CM in *Cancer J*, 18: 215–222. The authors apologize for this oversight.